## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

Check this box if no longer subject to Section 16. Form 4

FORM 4

or Form 5 obligations may contin	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									<u>  </u>	nours per re		0.5					
1. Name and Address of Reporting Person <sup>*</sup> <u>LEVIN ARTHUR A</u>						2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ ISIS ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Own X Officer (ajve title below) Other (sr				
(Last) (First) (Middle) 2292 FARADAY AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 07/01/2004									X Officer (give title below) Other (specify below) Vice President				
Street) CARLSBAD CA 92008				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individ X	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)					2. Transact Date (Month/Day	Execu	Execution Date,				1. Securities Acquired (A) or Disposed Of (I 3, 4 and 5)		ed Of (D) (Instr.	(Instr. 5. Amount of Securitie Beneficially Owned For Reported Transaction		6. Ownership Form: Direct (D) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr.	
					(wonth/bay				v	Amount		(A) or (D)	Price	Instr. 3 and 4)		(msu. 4)	4)	
Common Stock						004 07/	01/2004	J	v	2	272 <sup>(1)</sup> A \$		\$4.862	1,492	1,492			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	r. 2. Conversion or Exercise Price of Derivative Security		Execution Date, if any (Month/Day/Year)	4. Transad (Instr. 8)	ction Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expirat	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Derivative Security (Instr. 3 and 4			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following	Form: Direct (D) or Indirect	Indirect Beneficial	
				Code	v	(A)	(D)	Date Exercis		Expiration Date	Title		Amount or Number of Sha	ures	Reported Transactic (Instr. 4)	on(s)		

Explanation of Responses:

1. Reporting 272 shares acquired under the Isis Pharmaceuticals, Inc. 2000 Employee Stock Purchase Plan on July 1, 2004

Remarks:

B. Lynne Parshall, Attorney-in-Fact, for Arthur 07/02/2004

Date

A. Levin \*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Stanley T. Crooke and B. Lynne Parshall, signing individually, the undersigned (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Isis Pharmaceuticals, Inc. (1) (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best in The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, ( This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with 1

IN WITNESS WHEREOF, the undersigned has cause this Power of Attorney to be executed as of this 12th day of November, 2002.

/s/Arthur A. Levin